The DOI matches its Crossref record; 256 of the 259 references it cites were found in a registry or an index.
Therapeutically harnessing extracellular vesicles
Abstract
The field of extracellular vesicle (EV) research has developed rapidly over the last decade from the study of fundamental biology to a subject of significant clinical relevance. The potential of harnessing EVs in the diagnosis and treatment of diseases - including cancer and neurological and cardiovascular disorders - is now being recognized. Accordingly, the applications of EVs as therapeutic targets, biomarkers, novel drug delivery agents and standalone therapeutics are being actively explored. This Review provides a brief overview of the characteristics and physiological functions of the various classes of EV, focusing on their association with disease and emerging strategies for their therapeutic exploitation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In this context, EVs have surfaced as a promising avenue in the field of theranostics [50, 113–117].”
From Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions (2024) · cites this paper as [113]
In the citing paper
“In the realm of disease diagnosis and prognosis, the inherent capacity of EVs to encapsulate a spectrum of molecular cargo from parental cells positions them as promising liquid biopsy makers across various diseases, such as cancers, neurological diseases, and cardiovascular diseases [113].”
From Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions (2024) · cites this paper as [113]
In the citing paper
“Neurodegenerative diseases, such as AD characterized by Aβ and tau accumulation, PD associated with α-synuclein aggregates, and ALS marked by superoxide dismutase 1 (SOD 1) misfolding, are increasingly understood in the context of sEVs involvement [45, 113, 129].”
From Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions (2024) · cites this paper as [113]
In the citing paper
“The utilization of EVs as therapeutic delivery vehicles within the CNS has mainly concentrated on two distinct strategies: first, leveraging native EVs that inherently possess therapeutic factors, and second, custom-engineering EVs to encapsulate and transport specific therapeutic agents.”
From Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions (2024) · cites this paper as [113]
In the citing paper
“Exosomes derived from human bone marrow mesenchymal stem/stromal cells (BMSCs) have been created as FDA-approved medication transport carriers, owing to their strong security assessment and limited immunogenic characteristics.”
From Emerging role of exosomes in cancer therapy: progress and challenges (2025) · cites this paper as [206]
Citations
Cites
1 retracted
Ngolab, J., Trinh, I., Rockenstein, E., Mante, M., Florio, J., Trejo, M., Masliah, D., Adame, A., Masliah, E., & Rissman, R. A. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0445-5 · Cited by 200
RetractedValadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J. J., & Lötvall, J. O. (2007) · Nature Cell Biology · doi:10.1038/ncb1596 · Cited by 12,834
Théry, C., Witwer, K. W., Aikawa, E., Alcaraz, M. J., Anderson, J. D., Andriantsitohaina, R., Antoniou, A., Arab, T., Archer, F., Atkin‐Smith, G. K., et al. (2018) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2018.1535750 · Cited by 11,099
Self-citationStaging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
The biology , function , and biomedical applications of exosomes
Kalluri, R., & LeBleu, V. S. (2020) · Science · doi:10.1126/science.aau6977 · Cited by 10,770
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Shedding light on the cell biology of extracellular vesicles
van Niel, G., D'Angelo, G., & Raposo, G. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.125 · Cited by 8,369
Biological properties of extracellular vesicles and their physiological functions
Yáñez‐Mó, M., Siljander, P. R. ‐., Andreu, Z., Bedina Zavec, A., Borràs, F. E., Buzas, E. I., Buzas, K., Casal, E., Cappello, F., Carvalho, J., et al. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.27066 · Cited by 5,926
Astrocyte-endothelial interactions at the blood-brain barrier
Abbott, N. J., Rönnbäck, L., & Hansson, E. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1824 · Cited by 5,595
Novel Proteinaceous Infectious Particles Cause Scrapie
Prusiner, S. B. (1982) · Science · doi:10.1126/science.6801762 · Cited by 5,118
Research works printed but not linked: 1
- Banizs, A. B. et al. In vitro evaluation of endothelial exosomes as carriers for small interfering ribonucleic acid delivery. Int. J. Nanomed. 9, 4223–4230 (2014).
Cited by
Bacteria in cancer initiation, promotion and progression
El Tekle, G., & Garrett, W. S. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00594-2 · Cited by 343
Extracellular vesicles: a rising star for therapeutics and drug delivery
Du, S., Guan, Y., Xie, A., Yan, Z., Gao, S., Li, W., Rao, L., Chen, X., & Chen, T. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01973-5 · Cited by 314
Comprehensive isolation of extracellular vesicles and nanoparticles
Zhang, Q., Jeppesen, D. K., Higginbotham, J. N., Franklin, J. L., & Coffey, R. J. (2023) · Nature Protocols · doi:10.1038/s41596-023-00811-0 · Cited by 294
Exploiting the biogenesis of extracellular vesicles for bioengineering and therapeutic cargo loading
Rädler, J., Gupta, D., Zickler, A., & Andaloussi, S. E. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.02.013 · Cited by 282
Emerging role of exosomes in cancer therapy: progress and challenges
Li, J., Wang, J., & Chen, Z. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02215-4 · Cited by 297
Metadata
- Authors
- Cheng, L., & Hill, A. F.
- Affiliations
- La Trobe University (AU)
- Corresponding author
- Hill, Andrew F.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2022-03-02
- Volume
- 21
- Issue
- 5
- Pages
- 379-399
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W4214933741
- Cited by
- 737
- References
- 259
- Citations by year
- 2026: 119 · 2025: 181 · 2024: 199 · 2023: 172 · 2022: 66
- FWCI
- 16.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Victoria University Research Repository (Victoria University) (submittedVersion)
- Figshare (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Caveolin-1 and cellular processes
- Keywords
- extracellular vesicles, drug delivery, biomarkers, cancer, neurological disorders, cardiovascular disease
- MeSH terms
- Extracellular Vesicles, Cardiovascular Diseases, Humans, Neoplasms, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutically harnessing extracellular vesicles. https://app.cochat.ai/papers/10.1038/s41573-022-00410-w
- The paper
- Cheng, L., & Hill, A. F. (2022). Therapeutically harnessing extracellular vesicles. Nature Reviews Drug Discovery. https://doi.org/10.1038/s41573-022-00410-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.